Month: August 2021

Reports Record Second Quarter Revenue and Profit FREMONT, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Corsair Gaming, Inc. (NASDAQ:CRSR) (“Corsair”), a leading global provider and innovator of high-performance gear for gamers and content creators, today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 HighlightsNet revenue was $472.9 million, an increase of 24.3% year-over-year. Gamer and creator peripherals segment net revenue was $155.2 million, an increase of 40.9% year-over-year. Gaming components and systems segment net revenue was $317.7 million, an increase of 17.6% year-over-year. Gross profit was $130.4 million, an increase of 24.1% year-over-year, with gross margin of 27.6%, flat year-over-year. Gamer and creator peripherals segment gross profit was $54.6 million, an increase...

— Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities —— EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics trial and Phase 3 trials of weekly setmelanotide formulation all expected to initiate in 2H 2021 —— Updated Uncovering Rare Obesity genetic test with expanded gene panel launched in July — — Company to host conference call at 8 a.m. ET today — CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide...

~ Successful Mount Holly integration contributed favorably to Q2 results ~ Acquisition of Jacob Holm will add scale and new technologies, enhancing engineered materials portfolio CHARLOTTE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT), a leading global supplier of engineered materials, today reported net income for the three months ended June 30, 2021 of $1.5 million, or $0.03 per diluted share, compared with a loss of $2.3 million, or a loss of $0.05 per share, in the same period a year ago. The results include the acquisition of Georgia-Pacific’s U.S. nonwovens business (“Mount Holly”) effective May 13, 2021. Adjusted earnings from continuing operations for the three months ended June 30, 2021 and 2020, were $8.0 million, or $0.18 per share, compared with $9.9 million, or $0.22 per share, respectively....

Inter Pipeline Ltd. (“IPL”) shareholders must tender their shares by August 6th to receive the significant premium available under Brookfield Infrastructure’s Offer to purchase the company The IPL Board of Directors have recommended that IPL shareholders accept the Offer from Brookfield Infrastructure Offer represents a 50% premium to IPL’s unaffected share price1 and has received all key regulatory and financing approvals with the ability to close within three business days of the Offer expiry (subject to the modified statutory minimum condition) Shareholders may elect up to 100% cash consideration, totalling C$20.00 per share of IPL without being subject to proration or 0.250 of a class A exchangeable subordinated voting share of Brookfield Infrastructure Corporation (a “BIPC Share”), subject to proration Questions or Need Assistance?...

WATERLOO, Ontario, Aug. 03, 2021 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX: DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its second-quarter fiscal 2022 financial results after market close on Wednesday, September 8, 2021. Members of Descartes’ executive management team will host a conference call to discuss the company’s financial results at 5:00 p.m. ET on Wednesday, September 8. Designated numbers are +1 888 465-5079 for North America and +1 416 216-4169 for international, using Passcode 8565 668#. The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. Phone conference dial-in or webcast log-in is required approximately 10 minutes beforehand. Replays of the conference...

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president and chief scientific officer of Beam, will participate in a panel titled, “So Let it Be (Re)Written – Updates in Gene Modulation” during the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 10, 2021 at 9:10 a.m. ET. The live webcast will be available in the investor section of the company’s website at www.beamtx.com. The webcast will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this...

SANTA BARBARA, CA , Aug. 03, 2021 (GLOBE NEWSWIRE) — SunHydrogen, Inc. (OTC:HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, this week shared a new video that showcases its nanoparticle-based green hydrogen technology, placing it in the context of the fast-growing global hydrogen market. “For all our investors, but especially our newest followers and first-time viewers, we hope this introductory video serves as a fresh look at where the future is headed and what sets us apart,” said Odessa Stork, Director of Communications at SunHydrogen, Inc. “We’re excited to continue utilizing video communication to connect with our audience across all platforms as we make progress toward commercialization.” The video highlights the efficiency and versatility that SunHydrogen’s technology...

Platform Study to Evaluate Mirdametinib as a Combination Therapy with Fulvestrant in Patients with ER+ Metastatic Breast Cancer and as a Monotherapy in Patients with Advanced Solid Tumors Harboring Activating Mutations in MEK1 or MEK2 STAMFORD, Conn., Aug. 03, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the Company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study sponsored by Memorial Sloan Kettering Cancer Center (MSK) and supported by SpringWorks exploring the compound both as a monotherapy and as a combination therapy in advanced solid tumors harboring MAPK-activating mutations. The trial, which is expected...

CharityHolmanCharity HolmanATLANTA, Aug. 03, 2021 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray”) (NYSE: GTN) has promoted Charity Holman to the position of General Manager of WVVA (NBC) in Bluefield, West Virginia. Charity succeeds Frank Brady, who recently retired as the station’s General Manager after more than 15 years with the television station and 47 years in broadcasting. Gray became the owner of WVVA upon its acquisition of Quincy Media, Inc. yesterday. Since joining WVVA in September 2006, Charity has held a number of sales positions for the station. She has served as the station’s General Sales Manager since 2014, and she added the position Station Manager to her responsibilities in January 2019. In her new role, Charity will maintain her role as General Sales Manager. Charity has long been active...

SUNNYVALE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading provider of customer engagement solutions, today announced that management is scheduled to present at the Oppenheimer Virtual 24th Annual Technology, Internet & Communications Conference on Monday, August 9, 2021 at 11:55 am PT, with virtual one-on-one meetings with investors held throughout the day. To access a live audio webcast or replay of eGain’s presentation, please click on the following link https://wsw.com/webcast/oppenheimer15/egan/2736150 or visit the investor relations section of eGain’s website at http://www.egain.com/company/investors/. For additional information or to schedule a meeting with eGain management, please contact either your Oppenheimer representative, or MKR Investor Relations, eGain’s investor relations firm, at...